← Eichor
Study identifier: NCT06347653 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

Condition: Nodal T-follicular Helper Cell Lymphoma  ·  Sponsor: Peking University

PhasePhase 2
Planned participants54
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This study is conducted to evaluate the efficacy and safety of linperlisib combined with CHOP regimen followed by autologous hematopoietic stem cell transplantation and linperlisib monotherapy maintenance for newly diagnosed nTFHL patients.

This description comes directly from the study's public registry record.

Talk to the study team

PING WEI LIU, Master  ·  0086-13522796323  ·  dreaming2217@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Bejing Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06347653